Nationwide Children's News Releases
Viewing: 31-40 of 99 | All
Apr 24, 2018
Nationwide Children’s Researcher Wins Distinguished Clinical Research Achievement Award
The Clinical Research (CR) Forum, a non-profit membership association of top clinical research experts and thought leaders from the nation’s leading academic health centers, presented the Distinguished Clinical Research Achievement Award to two outstanding studies at the Top Ten Clinical Research Achievement Awards on April 18th at the National Press Club in Washington, D.C.
Mar 27, 2018
Nationwide Children's Hospital Study Named Among Top Ten Clinical Research Achievement Awards by the Clinical Research Forum
The first clinical trial to test the functional replacement of the mutated gene responsible for SMA1 will be recognized at the 2018 Top Ten Clinical Research Achievement Awards at the National Press Club in Washington, D.C., on April 18, 2018.
Nov 01, 2017
Phase 1 Study Shows Encouraging Data for Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
A one-time intravenous infusion of the high dose of gene therapy extended the survival of patients with spinal muscular atrophy type 1 (SMA1) in a Phase 1 clinical trial, according to a study published today in the New England Journal of Medicine. The study was conducted by Researchers from Nationwide Children’s Hospital in collaboration with AveXis, Inc. and The Ohio State University College of Medicine.
Jan 10, 2017
Sarepta Therapeutics Enters Into License Agreement with Nationwide Childrens Hospital for Galgt2 Gene Therapy Program
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a license agreement with Nationwide Children’s Hospital, for their Galgt2 gene therapy program developed by researcher Paul Martin, PhD.
Jan 10, 2017
Sarepta Therapeutics Enters Into Research Agreement and Option Agreement with Nationwide Childrens Hospital for Microdystrophin Gene Therapy Program
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research agreement with Nationwide Children’s Hospital on their microdystrophin gene therapy program.
Jan 03, 2017
Flanigan Named to Neuromuscular, Gene Therapy Leadership Roles
Beginning January 1, 2017, Kevin Flanigan, MD, will become the director of the Center for Gene Therapy and the Neuromuscular Disorders program at Nationwide Children’s Hospital. Dr.
Oct 12, 2016
Nationwide Childrens Hospital Neuromuscular Disease Researchers Receive $7.5 Million NIH Grant
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health announced four new Centers of Research Translation awards today.
Oct 04, 2016
Perky Jerky® to Support Nationwide Childrens Hospital Beginning in October
Nationwide Children’s Hospital and Perky Jerky® announced today that from October through December, customers at 16 participating Kroger stores will have an opportunity to donate to Nationwide Children’s by purchasing Perky Jerky®.
Sep 26, 2016
Oligodendrocytes Induce Motor Neuron Death in ALS
A first-of-its-kind oligodendrocyte in vitro model shows that human cells normally supportive of motor neuron function play an active role in amyotrophic lateral sclerosis pathogenesis – and this discovery may point the way toward therapeutic timing and targets.
Sep 20, 2016
Nationwide Childrens Hospital Leads Effort for Gene Therapy Treatment for Duchenne Muscular Dystrophy
Sarepta Therapeutics announced yesterday that the FDA has granted accelerated approval for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Nationwide Children's Hospital was the sole original site for the clinical study that resulted in this approval, led by Dr.